Barrett’s esophagus is also called columnar epithelium lined lower oesophagus (CELLO). It is caused due to abnormal changes occur within the cell of the lower portion of the esophagus. The main reason for Barrett,s esophagus is chronic acid exposure from reflex esophagus. Mostly this kind of condition found in 5-10% patients who diagnosed for gastroesophageal reflux disease (GERD). Although, many of the patients with barrett’s esophagus do not have symptoms.
Symptoms: Barrett’s esophagus does not cause any particular symptoms, however it is associated with below mentioned symptoms. • heartburn • dysphagia • hematemesis • pain under the sternum where the esophagus meets the stomach • unintentional weight loss because eating is painful
Treatment: For barrett’s esophagus doctors will approach different types of treatment that is depend up on the severity of disease those includes medicines, Endoscopic ablative therapies, Endoscopic mucosal resection, Surgery. Doctors prefer acid supressing medicine like proton pump inhibitor; an Endoscopic ablative therapy is performing by using different methods those are Photodynamic therapy, Radiofrequency ablation; In endoscopic mucosal resection, your doctor lifts the Barrett’s tissue, injects a solution underneath or applies suction to the tissue, and then cuts the tissue off. The doctor then removes the tissue with an endoscope; many of the doctors prefer surgery because this is having very less complications.
Incidence of esophageal adenocarcinoma (EAC) has increased sharply in Western Europe and United States over the past three decades. Nearly all cases of EAC in the west are thought to be associated with Barrett’s esophagus (BE) at the time of diagnosis. Regions in the Henan province of China have one of world’s highest incidences of esophageal cancer, yet recent temporal trends in the relative rates of EAC with respect to esophageal squamous-cell carcinoma (ESCC), as well as its association with Barrett’s esophagus (BE), have not been reported. In this report, we present large-scale longitudinal clinical and histological data on 5401 esophageal cancers (EC) patients diagnosed during the recent 10-year period (2002–2011) at Henan Cancer Hospital, China. All 217 esophageal adenocarcinoma (EAC) patients from these 5401 EC patients were examined to better understand the relationship between Barrett’s esophagus (BE) and EAC. We found that EAC was relatively rare and accounted for approximately 5% of all esophageal cancers each year during 2002–2011. There is no evidence of significant temporal trends in the rate of EAC relative to ESCC. Only 10 out of 217 (4.6%) EAC cases were detected to have any evidence of Barrett’s esophagus.